So, on the strength of that trial, Blackman and Grant paid $1 million (plus $10 million in Day One stock) to Takeda and $2 ...

Daiichi Sankyo's European division has signed a partnership with German digital health company GAIA to sell a digital therapeutic (DTx) designed to support people with high cholesterol levels. The DTx ...

Alnylam is broadening its position in the area of RNA interference (RNAi) gene-silencing therapies for cardiovascular diseases via a partnership with Tenaya Therapeutics, claiming rights to use the ...

Chakravarthi AVPS, Chairman of the Federation of Pharma Entrepreneurs, provides an overview of global strategies to accelerate access to innovative therapies, bridging equity, regulation, and ...

The FDA has started a review of Hansa Biopharma's imlifidase for patients who need a kidney transplant, but for whom finding ...

Rumours earlier this week of an imminent takeover offer for Day One Biopharmaceuticals proved well-founded, but missed the mark on the identity of the acquirer. France's Servier has emerged as the ...

Cardiff, Wales-based Antiverse's computational platform has been set up to find antibodies against challenging drug targets, ...

Novo Nordisk has said it will invest DKK 3.2 billion (€432 million) in a manufacturing plant in Ireland that will be used to ...

Italy's AI Law establishes new criminal offenses, creating meaningful risks for US executives and employees. The law ...

Roche licensed petrelintide from Zealand last year for a hefty $1.4 billion upfront payment, adding it to a portfolio of half a dozen clinical-stage candidates, including dual GIP/GLP-1 agonist CT-388 ...

With the increase in wellness brands competing for audience attention, it’s more important than ever that pharma marketers tell their stories clearly and creatively, with a focus on educating ...

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 ...